A long acting injectable formulation based on combination of biodegradable poly(D,L-lactide-co-glycolide) microparticles comprising different PLGA polymers and Tacrolimus. The microparticles may include Tacrolimus, a first polymer and a second polymer, and the first and second polymer may differ from each other. Each of the first and second polymers may be a poly(D,L-lactide-co-glycolide) polymer. Each of the first and second polymers may have an identical lactide to glycolide ratio. Each of the first and second polymers may have a different molecular weight
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
2.
SUSTAINED RELEASE INJECTABLE PHARMACEUTICAL FORMULATION OF LEVOTHYROXINE AND PROCESS FOR PREPARATION THEREOF
A stable sustained release injectable formulation based on poly(D,L-lactide-co-glycolide) microparticles comprising levothyroxine is described. The formulation has a theoretical levothyroxine loading of at least 1.5% w/w. A process for preparing the microparticles is also described. The formulation may be used to control hypothyroidism in adults, congenital hypothyroidism in infants, and acquired hypothyroidism in children.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
3.
SUSTAINED RELEASE MICROPARTICLES AND PROCESS FOR THE PREPARATION THEREOF
The present invention relates to sustained release microparticle pharmaceutical formulations comprising a hydrophobic drug and a process for the preparation thereof.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising an antimicrobial agent such as Rifaximin or a pharmaceutical acceptable salt, derivative or polymorph thereof as the active ingredient. It also relates to an innovative process for the preparation thereof.
A61K 9/24 - Layered or laminated unitary dosage forms
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.
A process may allow the preparation of one or more viscous pharmaceutical formulations and an apparatus may be configured for implementing such a process. A gellable material may be introduced into one chamber, a vehicle may be introduced in the other and by alternately applying force to each chamber, mixing and homogenization may take place. The internal diameter of the connection equipment of the two chambers may be equal to the outlet internal diameters of the chambers. Each chamber may have different diameter, with the first chamber being larger than the second chamber, so as to allow the process to be executed in a simple and more convenient manner.
The present invention relates to a preservative free ophthalmic pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brimonidine or ophthalmological acceptable salts thereof alone or in combination with a therapeutically effective quantity of Timolol or ophthalmological acceptable salts thereof, to be used for the treatment of ocular hypertension and glaucoma.
The present invention relates to a stable preservative-free Cyclosporine emulsion in the form of eye drops and a process for the manufacturing thereof, packed in a container that ensures stability of the product for the treatment of keratoconjunctivitis sicca.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention relates to a stable sustained release injectable formulation based on poly(D,L-lactide-co-glycolide) microparticles comprising Levothyroxine. It also relates to a process for the preparation of microparticles and use to control hypothyroidism in adults, congenital hypothyroidism in infants and acquired hypothyroidism in children.
The present invention relates to a stable sustained release injectable formulation based on poly(D,L-lactide-co-glycolide) microparticles comprising Levothyroxine. It also relates to a process for the preparation of microparticles and use to control hypothyroidism in adults, congenital hypothyroidism in infants and acquired hypothyroidism in children.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Generic pharmaceutical preparation for the treatment of gout; Generic pharmaceutical preparations acting on the central nervous system; Generic pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Generic pharmaceutical preparations for animal skincare; Generic pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Generic pharmaceutical preparations for ocular or intraocular surgery; Generic pharmaceutical preparations for the treatment of heart rhythm disorders; Generic pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Generic pharmaceutical preparations for the treatment of infectious diseases; Generic pharmaceutical preparations for treating allergic rhinitis and asthma; Generic pharmaceutical preparations for treating diabetes; Generic pharmaceutical preparations for treating skin disorders; Generic pharmaceutical preparations for use in chemotherapy; Generic pharmaceutical preparations for use in dermatology; Generic pharmaceutical preparations for use in urology; Generic pharmaceutical preparations for wounds; Generic pharmaceutical preparations, namely, anticoagulants; Generic pharmaceutical preparations, namely, antidepressants; Generic pharmaceutical preparations, namely, appetite suppressants; Generic pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Generic pharmaceutical preparations, namely, a drug delivery system comprising polymer based oral tablets for the continuous release of a wide variety of therapeutic agents; Preparations for destroying parasites; Preparations for destroying vermin; Sanitary preparations for medical use; Self-adhesive dressings; Veterinary preparations, namely, pain relief medication
12.
PHARMACEUTICAL FORMULATION COMPRISING TACROLIMUS, METHOD FOR THE PREPARATION THEREOF AND USE
The present invention relates to a long acting injectable formulation based on combination of biodegradable poly(D,L-lactide-co-glycolide) microparticles comprising different PLGA polymers and Tacrolimus. It also relates to a process for the preparation of microparticles & use thereof.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
13.
PHARMACEUTICAL FORMULATION COMPRISING TACROLIMUS, METHOD FOR THE PREPARATION THEREOF AND USE
The present invention relates to a long acting injectable formulation based on combination of biodegradable poly(D,L-lactide-co-glycolide) microparticles comprising different PLGA polymers and Tacrolimus. It also relates to a process for the preparation of microparticles & use thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
14.
SOFT GEL CAPSULE COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR
The present invention relates to a method of manufacturing of an immediate release oral liquid formulation comprising ospemifene. Also relates to a self-emulsifying drug delivery system, a self-microemulsifying drug delivery system and a self-nanoemulsifying drug delivery system for oral administration comprising ospemifene and manufacturing methods thereof. Interestingly, the formulations presented in the invention avoid the need for food intake by the patient in need of such treatment previously required for increased bioavailability of Ospemifene tablet formulations.
The present invention relates to a stable preservative-free Cyclosporine emulsion in the form of eye drops and a process for the manufacturing thereof, packed in a container that ensures stability of the product for the treatment of keratoconjunctivitis sicca.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
16.
PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND METFORMIN AND METHOD OF PREPARATION THEREOF
The present invention relates to a solid pharmaceutical composition comprising a fixed dose combination of Sitagliptin or a pharmaceutically acceptable salt thereof and Metformin or a pharmaceutically acceptable salt thereof, for oral administration and a process for the preparation thereof. The pharmaceutical composition of the present invention is to be used for the treatment of Type 2 diabetes.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Next, milling of the Drug-Resin complex particles until particle size gets less than 250 μm, and then dry mixing of the Drug-Resin complex particles with excipients to form an internal phase. The excipients of the internal phase comprise a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. Next, mixing the internal phase with excipients of an external phase to form the powder, and then sifting the powder to eliminate any clumps.
The present invention relates to an immediate release stable pharmaceutical formulation for oral administration containing a therapeutically effective quantity of 5-chloro-N-({(5S)-2-oxo-3-[4-(3- oxo-4-morpholinyl)-phenyl]-l,3-oxazolidin-5-yl}-methyl)-2 -thiophenecarboxamide or a pharmaceutically acceptable salt thereof, and a method for the preparation thereof.
The present invention relates to a sustained release composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults.
The present invention relates to an immediate release stable pharmaceutical formulation for oral administration containing a therapeutically effective quantity of Teriflunomide or a pharmaceutically acceptable salt thereof, and a method for the preparation thereof.
The present invention relates to a sustained release and abuse proof composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults.
The present invention relates to a method of manufacturing of a prolonged release solid dispersion formulation comprising Tacrolimus or a pharmaceutically acceptable salt thereof. Furthermore it relates to the manufacturing process of such a dosage form.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
23.
SOLID DOSAGE FORM COMPRISING SITAGLIPTIN AND METHOD OF PREPARATION THEREOF
The present invention relates to a solid dosage form useful for the treatment of Type 2 diabetes. The main objective of the present invention is to provide tablets formulation comprising Sitagliptin or a pharmaceutically acceptable salt thereof that is robust and stable. An effective manufacturing process for the preparation of said tablets is also provided.
The present invention relates to a process for the preparation of viscous pharmaceutical formulations and to an apparatus for implementing the process. A gellable material is introduced into one chamber, a vehicle is introduced in the other and by alternately applying force to each chamber, mixing and homogenization takes place. The internal diameter of the connection equipment of the two chambers is equal to the outlet internal diameters of the chambers. And each chamber is chosen to have different diameter, with the first chamber being larger than the second chamber, so as to allow the process to be executed in a simple and more convenient manner.
A61P 5/02 - Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
A61P 5/04 - Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
A61P 5/08 - Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
25.
PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present invention relates to a preservative free ophthalmic pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brimonidine or ophthalmological acceptable salts thereof alone or in combination with a therapeutically effective quantity of Timolol or ophthalmological acceptable salts thereof, to be used for the treatment of ocular hypertension and glaucoma.
The present invention relates to a novel process for the preparation of Tapentadol and intermediate compound 2R,3R)-3-(-methoxyphenyl)-N,N,2-trimethylpentanamine (compound of formula IIa).
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
C07C 217/62 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
C07C 215/54 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
28.
PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE
The present invention relates to a stable preservative-free Cyclosporine emulsion in the form of eye drops and a process for the manufacturing thereof, packed in a container that ensures stability of the product for the treatment of keratoconjunctivitis sicca.
The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
The present invention relates to a sustained release and abuse proof composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults.
The present invention relates to a sustained release composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults.
The present invention relates to a method of manufacturing of a prolonged release solid dispersion formulation comprising Tacrolimus or a pharmaceutically acceptable salt thereof. Furthermore it relates to the manufacturing process of such a dosage form.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
33.
Preservative free pharmaceutical compositions for ophthalmic administration
The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The present invention relates to a solid pharmaceutical formulation of Vildagliptin or a pharmaceutically acceptable salt thereof in combination with Metformin or a pharmaceutically acceptable salt thereof, to be used for the treatment of Type2 diabetes.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of Febuxostat MgO complex to enhance API solubility. It also relates to a process for the preparation thereof
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration containing a therapeutically effective amount of Lingolimod HCl in combination with inorganic salts in order to avoid any interaction with the active ingredient and formation of degradation products. It also relates to a process for the preparation thereof.
The present invention relates to a delayed release pharmaceutical composition comprising a fumaric acid ester such as Dimethyl fumarate in the form of gastro-resistant tablets filled into hard gelation capsule.
The present invention relates to a stable pharmaceutical formulation in the form of tablet for oral administration comprising a therapeutically effective amount of an iron chelating agent, in particular Deferasirox in an amount higher than 60% by weight based on the total weight of the medicament and an effective amount of a non-ionic surfactant. It also relates to a process for the preparation thereof.
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.
C07C 213/00 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
C07C 213/08 - Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
41.
SOFT GEL CAPSULE COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR
The present invention relates to a method of manufacturing of an immediate release oral liquid formulation comprising ospemifene. Also relates to a self-emulsifying drug delivery system, a self-mircoemulsifying drug delivery system and a self-nanoemulsifying drug delivery system for oral administration comprising ospemifene and manufacturing methods thereof. Interestingly, the formulations presented in the invention avoid the need for food intake by the patient in need of such treatment previously required for increased bioavailability of Ospemifene tablet formulations.
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
42.
Process for preparing biodegradable polymers of high molecular weight
A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
The present invention relates to an ophthalmic aqueous composition for the decrease of intraocular pressure in patients with ocular hypertension or open angle glaucoma containing a combination of Brinzolamide and Brimonidine and a method for preparation thereof. The invention as currently presented has a significant advantage over ophthalmic compositions already known in the art. More particularly the present invention relates to a multi-dose ophthalmic aqueous composition comprising a borate, a single polyol and benzalkonium chloride as an antimicrobial agent.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
The present invention relates to a preservative-free ophthalmic composition for the reduction of elevated intraocular pressure containing Latanoprost or a combination of Latanoprost and Timolol and to a process for preparing such compositions.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
46.
PHARMACEUTICAL COMPOSITION COMPRISING VILDAGLIPTIN AND METHOD OF PREPARATION THEREOF
The present invention relates to a solid pharmaceutical formulation of Vildagliptin to be used for the treatment of Type2 diabetes. The main objective of the present invention is to provide a formulation of Vildagliptin that is stable and robust and the manufacturing process is easy and cost effective.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
47.
PROCESS FOR PREPARING BIODEGRADABLE POLYMERS OF HIGH MOLECULAR WEIGHT
A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction. In an embodiment, provided is a method polymerization of lactide and glycolide monomers, comprising the step of performing polymerization under stirring, in the presence of an organic solvent, an initiator, wherein the initiator is a metal catalyst and optionally a co-initiator, wherein the polymerization is performed in a system which does not allow air or other gas exchange between the inner and the outer part of it once it is sealed.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of an antiemetic agent in particular Aprepitant and an effective amount of surface stabilizer in order to improve bioavailability. It also relates to a process for the preparation thereof.
The present invention relates to a delayed release pharmaceutical composition comprising a fumaric acid ester such as Dimethyl fumarate in the form of gastro-resistant tablets filled into hard gelation capsule.
The present invention relates to a delayed release pharmaceutical composition comprising a fumaric acid ester such as Dimethyl fumarate in the form of gastro-resistant tablets filled into hard gelation capsule.
The present invention relates to an immediate release stable pharmaceutical formulation comprising a therapeutically effective amount of Prasugrel besylate and an amount of surfactant.
A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
53.
PHARMACEUTICAL COMPOSITION COMPRISING A NON-PURINE SELECTIVE INHIBITOR OF XANTHINE OXIDASE AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a non- purine selective inhibitor of xanthine oxidase, in particular Febuxostat and an effective amount of an alkalizing agent. It also relates to a process for the preparation thereof.
The present invention relates to the field of drug delivery and, particularly, to alternative processes for preparing ophthalmic compositions of Brinzolamide or pharmaceutical acceptable salts thereof.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 31/00 - Medicinal preparations containing organic active ingredients
55.
PROCESS FOR PREPARING COMPOUNDS USEFUL AS INTERMEDIATES FOR THE PREPARATION OF RALTEGRAVIR
The invention discloses a novel and selective methylation process used in the preparation of Raltegravir and intermediates. Further disclosed is an improved method for the reaction of intermediate amine compound of formula IIb with oxadiazole intermediate compound of formula V.
C07D 239/557 - Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to a preservative-free ophthalmic composition for the reduction of elevated intraocular pressure containing Latanoprost or a combination of Latanoprost and Timolol and to a process for preparing such compositions.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
57.
PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to controlled release pharmaceutical formulations comprising an atypical antipsychotic agent such as Paliperidone in the form of capsule filled with mini-tablets that provide zero order drug release. It also relates to a process for the preparation thereof.
A novel process for the preparation of a long acting injectable composition based on biodegradable poly(D,L-lactide-co-glycolide) microspheres comprising peptide active pharmaceutical ingredients.
The present invention relates to a preservative free ophthalmic pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Bimatoprost or ophthalmological acceptable salts thereof and a therapeutically effective quantity of Timolol or ophthalmological acceptable salts thereof, to be used for the treatment of ocular hypertension and glaucoma.
The present invention relates to water dispersible mini-tablets of Enalapril or a pharmaceutically acceptable salt thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined as 0 to 18 years of age. The water dispersible mini-tablets of Enalapril further include a disintegrant, a diluent, a lubricant and a glidant. The active ingredient is distributed evenly in the mini-tablet and the disintegrant comprises Crospovidone. The mini-tablet has a diameter of 3 mm and disintegrates in less than 15 seconds in water.
A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
A61K 9/00 - Medicinal preparations characterised by special physical form
B65B 1/00 - Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
B65B 63/02 - Auxiliary devices, not otherwise provided for, for operating on articles or materials to be packaged for compressing or compacting articles or materials prior to wrapping or insertion in containers or receptacles
61.
Pediatric powder for oral suspension containing antiviral agent and method for the preparation thereof
The present invention relates to a pediatric powder for reconstitution as suspension for oral administration comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
63.
PHARMACEUTICAL COMPOSITION COMPRISING DARUNAVIR AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to an immediate release pharmaceutical formulation comprising Darunavir. It also relates to a process for the preparation thereof.
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
The present invention relates to a novel process for the preparation of tryptamine, its substituted derivatives and intermediates for the preparation of them.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a triazole antifungal agent or pharmaceutical acceptable salt thereof, in particular Voriconazole and an effective amount of a solubility enhancing agent. It also relates to a process for the preparation thereof.
The present invention relates to controlled release pharmaceutical formulations comprising an atypical antipsychotic agent such as Paliperidone or pharmaceutical acceptable salt thereof in the form of a multi-layer tablet that provides zero order drug release. It also relates to a process for the preparation thereof.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration containing a therapeutically effective amount of Ivabradine HCl polymorph IV or δ in combination with moisture protective excipients and/or low or non- hygroscopic anhydrous excipients in order to avoid polymorphic transformation of the active ingredient. It also relates to a process for the preparation thereof.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
68.
PHARMACEUTICAL COMPOSITION CONTAINING AN ECHINOCANDIN ANTIFUNGAL AGENT AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to an aqueous solution comprising an echinocandin antifungal agent such as Caspofungin acetate, as the active ingredient, a buffering agent and at least a diluent/bulking agent. It also relates to the lyophilization of such solution in order to retrieve a dry powder for reconstitution prior to use.
C07K 7/56 - Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
The present invention relates to a stable pharmaceutical formulation for oral administration comprising a therapeutically effective amount of Atomoxetine or a pharmaceutically acceptable salt or polymorph thereof with an effective amount of a silicon dioxide that improves suspendability of the active pharmaceutical ingredient.
The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
The present invention relates to novel preparation methods for Topiroxostat through novel intermediates comprising novel methods for the formation of the triazole ring and for the cyanation of the pyridyl ring.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61P 13/00 - Drugs for disorders of the urinary system
72.
PHARMACEUTICAL COMPOSITION COMPRISING APREPITANT AND METHOD FOR THE PREPARATION THEREOF
Amorphous solid dispersions significantly improve solubility problems associated with Aprepitant. Finished dosage forms as well as processes for the preparation thereof are provided.
The present inventions relates to a solid pharmaceutical dosage form comprising Levodopa/Entacapone/Carbidopa, or pharmaceutically acceptable salts or hydrates thereof, characterized in that the active agents are stabilized with the use of dextrates.
The present invention relates to preparation of biodegradable microparticles formed from polylactide-polyglycolide copolymers (PLGA) polymer and how to achieve sigmoidal release of active pharmaceutical compound from the microparticles. In particular, the present invention relates to emulsification of an inner/oil phase to an outer/water phase followed by quenching and a single drying step for the preparation of microparticles having a preferred release profile of preferably basic/nucleophilic compounds such as risperidone. Alternatively the present invention is also suitable for hydrophobic compounds that have poor water-solubility and a high drug loading of >20% w/w is required. The release profile can be controlled by adjusting the degree of saturation of the outer/water phase with the organic solvent used in the inner/oil phase, the polymer concentration of the inner/oil phase and the temperature at the quenching step. In particular, an initial lag phase and a substantially sigmoidal release profile are achieved by using an outer aqueous phase over saturated with the solvent used in the inner phase at emulsification step, in combination with a low temperature during quenching.
C08J 3/14 - Powdering or granulating by precipitation from solutions
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
76.
PRESERVATIVE FREE OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING PROPRANOLOL FOR USE IN TREATMENT OF RETINOPATHY OF PREMATURITY AND METHOD OF PREPARATION THEREOF
The present invention relates to a preservative free ophthalmic aqueous composition containing the beta-blocker propranolol or pharmaceutically acceptable salts thereof for the treatment of retinopathy of prematurity in a pediatric population of a specific age and a method for preparation thereof. Moreover, such a preservative-free formulation is packed in a container that ensures its physical and chemical stability.
The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
The present invention relates to a pediatric chewable tablet comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.
The present invention relates to water dispersible mini-tablets of Enalapril or a pharmaceutically acceptable salt thereof for use in the treatment of hypertension in a pediatric formulation. The pediatric formulation is defined as 0 to 18 years of age. The present invention also provides a method of manufacturing of such dosage form.
The present invention relates to a pediatric powder for reconstitution as suspension for oral administration comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Generic pharmaceutical preparation for the treatment of gout; Generic pharmaceutical preparations acting on the central nervous system; Generic pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Generic pharmaceutical preparations for animal skincare; Generic pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Generic pharmaceutical preparations for ocular or intraocular surgery; Generic pharmaceutical preparations for the treatment of heart rhythm disorders; Generic pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Generic pharmaceutical preparations for the treatment of infectious diseases; Generic pharmaceutical preparations for treating allergic rhinitis and asthma; Generic pharmaceutical preparations for treating diabetes; Generic pharmaceutical preparations for treating skin disorders; Generic pharmaceutical preparations for use in chemotherapy; Generic pharmaceutical preparations for use in dermatology; Generic pharmaceutical preparations for use in urology; Generic pharmaceutical preparations for wounds; Generic pharmaceutical preparations, namely, anticoagulants; Generic pharmaceutical preparations, namely, antidepressants; Generic pharmaceutical preparations, namely, appetite suppressants. Generic pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Generic pharmaceutical preparations, namely, a drug delivery system comprising polymerbased oral tablets for the continuous release of a wide variety of therapeutic agents; Preparations for destroying parasites; Preparations for destroying vermin; Sanitary preparations for medical use; Self adhesive dressings; Veterinary preparations, namely, pain relief medication Providing advertising, marketing and promotional services for the generic pharmaceutical and medical industry. Providing advertising, marketing and promotional services for the generic pharmaceuticals and medical products of others; Providing information on the topic of promoting patient, physician and employee satisfaction via a global computer network Education services, namely, mentoring in the field of generic pharmaceuticals, diagnostic preparations, veterinary preparations, proprietary medicines, toiletries and cosmetics; Educational services, namely, providing classes, seminars and workshops in the fields of generic pharmaceuticals, diagnostic preparations, veterinary preparations, proprietary medicines, toiletries and cosmetic industries; Providing continuing medical education courses Medical and scientific research services in the field of cancer treatment and diagnosis; Generic pharmaceutical drug development services; generic Pharmaceutical research services; Professional consulting services and advice about agricultural chemistry; Scientific consulting and research services relating to foods and dietary supplements; Technical consultancy in relation to research services relating to foods and dietary supplements; Scientific investigations for medical purposes in the field of generic pharmaceuticals; Scientific research in the field of generic pharmaceuticals; Scientific research and development in the field of generic pharmaceuticals Medical services; Providing health care information by telephone; Providing health care information by telephone and the Internet; Providing health information; Providing information about beauty; Providing medical information, consultancy and advisory services in the field of generic pharmaceuticals; Veterinary services
05 - Pharmaceutical, veterinary and sanitary products
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Generic pharmaceutical preparation for the treatment of gout; Generic pharmaceutical preparations acting on the central nervous system; Generic pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Generic pharmaceutical preparations for animal skincare; Generic pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Generic pharmaceutical preparations for ocular or intraocular surgery; Generic pharmaceutical preparations for the treatment of heart rhythm disorders; Generic pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Generic pharmaceutical preparations for the treatment of infectious diseases; Generic pharmaceutical preparations for treating allergic rhinitis and asthma; Generic pharmaceutical preparations for treating diabetes; Generic pharmaceutical preparations for treating skin disorders; Generic pharmaceutical preparations for use in chemotherapy; Generic pharmaceutical preparations for use in dermatology; Generic pharmaceutical preparations for use in urology; Generic pharmaceutical preparations for wounds; Generic pharmaceutical preparations, namely, anticoagulants; Generic pharmaceutical preparations, namely, antidepressants; Generic pharmaceutical preparations, namely, appetite suppressants. Generic pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Generic pharmaceutical preparations, namely, a drug delivery system comprising polymerbased oral tablets for the continuous release of a wide variety of therapeutic agents; Preparations for destroying parasites; Preparations for destroying vermin; Sanitary preparations for medical use; Self adhesive dressings; Veterinary preparations, namely, pain relief medication Providing advertising, marketing and promotional services for the generic pharmaceutical and medical industry. Providing advertising, marketing and promotional services for the generic pharmaceuticals and medical products of others; Providing information on the topic of promoting patient, physician and employee satisfaction via a global computer network Education services, namely, mentoring in the field of generic pharmaceuticals, diagnostic preparations, veterinary preparations, proprietary medicines, toiletries and cosmetics; Educational services, namely, providing classes, seminars and workshops in the fields of generic pharmaceuticals, diagnostic preparations, veterinary preparations, proprietary medicines, toiletries and cosmetic industries; Providing continuing medical education courses Medical and scientific research services in the field of cancer treatment and diagnosis; Generic pharmaceutical drug development services; generic Pharmaceutical research services; Professional consulting services and advice about agricultural chemistry; Scientific consulting and research services relating to foods and dietary supplements; Technical consultancy in relation to research services relating to foods and dietary supplements; Scientific investigations for medical purposes in the field of generic pharmaceuticals; Scientific research in the field of generic pharmaceuticals; Scientific research and development in the field of generic pharmaceuticals Medical services; Providing health care information by telephone; Providing health care information by telephone and the Internet; Providing health information; Providing information about beauty; Providing medical information, consultancy and advisory services in the field of generic pharmaceuticals; Veterinary services
83.
PHARMACEUTICAL COMPOSITION COMPRISING A TRIAZOLE ANTIFUNGAL AGENT AND METHOD FOR PREPARATION THEREOF
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a triazole antifungal agent or pharmaceutical acceptable salt thereof, in particular Voriconazole and an effective amount of a solubility enhancing agent. It also relates to a process for the preparation thereof.
The present invention relates to the implementation of a new method for manufacturing solid dosage forms for oral administration comprising poorly water soluble active ingredients which overcomes the associated solubility problems and affords improved dissolution profile.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A novel process for the preparation of a long acting injectable composition based on biodegradable poly(D,L-lactide-co-glycolide) microspheres comprising peptide active pharmaceutical ingredients.
A novel process for the preparation of a long acting injectable composition based on biodegradable poly(D,L-lactide-co-glycolide) microspheres comprising peptide active pharmaceutical ingredients.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a combination of a therapeutically effective amount of a N-containing bisphosphonate, in particular Alendronate or pharmaceutical acceptable salt, derivative or hydrate thereof and Cholecalciferol, which is free of colloidal silicon dioxide and is prepared by dry granulation process in order to inhibit Cholecalciferol degradation.
The present invention relates to an immediate release tablet composition comprising an atypical antipsychotic agent such as Aripiprazole or a pharmaceutical acceptable salt thereof as the active ingredient and an effective amount of at least one pharmaceutically acceptable water soluble and at least one water insoluble diluent. It also relates to a process for the preparation thereof.
The present invention relates to a fast dissolving tablet comprising a therapeutically effective amount of a phosphate binding polymer, such as sevelamer or pharmaceutically acceptable salt or derivative thereof, that exhibit limited swelling in the oral cavity, has pleasant taste and mouth feel, high phosphate binding capacity with fast binding kinetics and require limited amount of water intake. A process for the preparation thereof is disclosed.
The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
92.
A NOVEL PROCESS FOR THE PREPARATION OF CHIRAL CYCLOPENTANONE INTERMEDIATES
C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
C07C 251/40 - Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
C07F 7/18 - Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
93.
NOVEL PROCESS FOR THE PREPARATION OF EZETIMIBE INTERMEDIATES
C07C 29/143 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of ketones
The present invention relates to a novel preparation method for 2-(3-cyano-4-isobutoxyphenyl)- 4-methyl-1,3-thiazole-5-carboxylic acid (Febuxostat) via novel and high yielded conversion of a formyl group in to a cyano group.
The present invention relates to a novel process for the preparation of tetralin and naphthalene derivatives of formula (IV), including Agomelatine and pharmaceutical acceptable salts thereof. Such compounds are considered to be interesting either as useful building blocks or due to their biological activity. The compounds of formula (IV) are prepared from compounds of formula (I) via intermediates (III) by allylic rearrangement.
C07C 233/18 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 41/18 - Preparation of ethers by reactions not forming ether-oxygen bonds
C07C 41/22 - Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogenPreparation of ethers by reactions not forming ether-oxygen bonds by substitution of halogen atoms by other halogen atoms
C07C 43/247 - Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring and to a carbon atom of a ring, other than a six-membered aromatic ring containing halogen
97.
PREPARATION OF POLYLACTIDE-POLYGLYCOLIDE MICROPARTICLES HAVING A SIGMOIDAL RELEASE PROFILE
The present invention relates to preparation of biodegradable microparticles formed from polylactide-polyglycolide copolymers (PLGA) polymer and how to achieve sigmoidal release of active pharmaceutical compound from the microparticles. In particular, the present invention relates to emulsification of an inner/oil phase to an outer/water phase followed by quenching and a single drying step for the preparation of microparticles having a preferred release profile of, preferably basic/nucleophilic compounds such as risperidone. Alternatively the present invention is also suitable for hydrophobic compounds that have poor water-solubility and a high drug loading of >20%w/w is required. The release profile can be controlled by adjusting the degree of saturation of the outer/water phase with the organic solvent used in the inner/oil phase, the polymer concentration of the inner/oil phase and the temperature at the quenching step. In particular, an initial lag phase and a substantially sigmoidal release profile are achieved by using an outer aqueous phase over saturated with the solvent used in the inner phase at emulsification step, in combination with a low temperature during quenching.
The present invention relates to preparation of biodegradable microparticles formed from polylactide-polyglycolide copolymers (PLGA) polymer and how to achieve sigmoidal release of active pharmaceutical compound from the microparticles. In particular, the present invention relates to emulsification of an inner/oil phase to an outer/water phase followed by quenching and a single drying step for the preparation of microparticles having a preferred release profile of, preferably basic/nucleophilic compounds such as risperidone. Alternatively the present invention is also suitable for hydrophobic compounds that have poor water-solubility and a high drug loading of >20%w/w is required. The release profile can be controlled by adjusting the degree of saturation of the outer/water phase with the organic solvent used in the inner/oil phase, the polymer concentration of the inner/oil phase and the temperature at the quenching step. In particular, an initial lag phase and a substantially sigmoidal release profile are achieved by using an outer aqueous phase over saturated with the solvent used in the inner phase at emulsification step, in combination with a low temperature during quenching.
The present invention relates to pharmaceutical compositions for parenteral administration comprising Voriconazole or pharmaceutical acceptable salt thereof as the active ingredient and a solubilizing agent such as hydroxypropyl beta cyclodextrin in order to achieve increased solubility of the active ingredient. The present invention also provides a method of preparation of such composition.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
100.
PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to orally dispersible pharmaceutical composition comprising an atypical antipsychotic agent such as Aripiprazole or a pharmaceutical acceptable salt thereof as the active ingredient and an effective amount of at least one pharmaceutically acceptable water soluble and at least one water insoluble diluent. It also relates to a process for the preparation thereof.
